Lack of In Vitro and In Vivo Recognition of Francisella tularensis Subspecies Lipopolysaccharide by Toll-Like Receptors

ABSTRACT Francisella tularensis is an intracellular gram-negative bacterium that is highly infectious and potentially lethal. Several subspecies exist of varying pathogenicity. Infection by only a few organisms is sufficient to cause disease depending on the model system. Lipopolysaccharide (LPS) of gram-negative bacteria is generally recognized by Toll-like receptor 4 (TLR4)/MD-2 and induces a strong proinflammatory response. Examination of human clinical F. tularensis isolates revealed that human virulent type A and type B strains produced lipid A of similar structure to the nonhuman model pathogen of mice, Francisella novicida. F. novicida LPS or lipid A is neither stimulatory nor an antagonist for human and murine cells through TLR4 or TLR2. It does not appear to interact with TLR4 or MD-2, as it is not an antagonist to other stimulatory LPS. Consistent with these observations, aerosolization of F. novicida LPS or whole bacteria induced no inflammatory response in mice. These results suggest that poor innate recognition of F. tularensis allows the bacterium to evade early recognition by the host innate immune system to promote its pathogenesis for mammals.

[1]  S. Michalek,et al.  Immunologic Consequences of Francisella tularensis Live Vaccine Strain Infection: Role of the Innate Immune Response in Infection and Immunity1 , 2006, The Journal of Immunology.

[2]  M. Apicella,et al.  Basis for the Failure of Francisella tularensis Lipopolysaccharide To Prime Human Polymorphonuclear Leukocytes , 2006, Infection and Immunity.

[3]  C. García-Rodríguez,et al.  Francisella tularensis LPS induces the production of cytokines in human monocytes and signals via Toll-like receptor 4 with much lower potency than E. coli LPS. , 2006, International immunology.

[4]  M. Muroi,et al.  Structural Regions of MD-2 That Determine the Agonist-Antagonist Activity of Lipid IVa* , 2006, Journal of Biological Chemistry.

[5]  A. Sjöstedt,et al.  Virulence comparison in mice of distinct isolates of type A Francisella tularensis. , 2006, Microbial pathogenesis.

[6]  C. Coban,et al.  Manifold Mechanisms of Toll-Like Receptor-Ligand Recognition , 2005, Journal of Clinical Immunology.

[7]  Richard W Titball,et al.  Vaccination strategies for Francisella tularensis. , 2005, Advanced drug delivery reviews.

[8]  M. Forsman,et al.  Evolution of Subspecies of Francisella tularensis , 2005, Journal of bacteriology.

[9]  A. Sjöstedt,et al.  Worldwide Genetic Relationships among Francisella tularensis Isolates Determined by Multiple-Locus Variable-Number Tandem Repeat Analysis , 2004, Journal of bacteriology.

[10]  B. Gibson,et al.  Novel Modification of Lipid A of Francisella tularensis , 2004, Infection and Immunity.

[11]  Samuel I. Miller,et al.  Respiratory epithelial cells regulate lung inflammation in response to inhaled endotoxin. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[12]  D. Persing,et al.  Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents , 2004, Expert opinion on biological therapy.

[13]  Makiko Kobayashi,et al.  Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. , 2004, International immunology.

[14]  A. Wiese,et al.  Endotoxins: relationships between structure, function, and activity. , 2004, Current topics in medicinal chemistry.

[15]  Samuel I. Miller,et al.  Variation in lipid A structure in the pathogenic yersiniae , 2004, Molecular microbiology.

[16]  H. D. Liggitt,et al.  Cutting Edge: Myeloid Differentiation Factor 88 Is Essential for Pulmonary Host Defense against Pseudomonas aeruginosa but Not Staphylococcus aureus1 , 2004, The Journal of Immunology.

[17]  M. Trent,et al.  Biosynthesis, transport, and modification of lipid A. , 2004, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[18]  Tara L. Kieffer,et al.  Francisella novicida LPS has greater immunobiological activity in mice than F. tularensis LPS, and contributes to F. novicida murine pathogenesis. , 2003, Microbes and infection.

[19]  R. Titball,et al.  Will the enigma of Francisella tularensis virulence soon be solved? , 2003, Trends in microbiology.

[20]  A. Sjöstedt,et al.  Discrimination of Human Pathogenic Subspecies of Francisella tularensis by Using Restriction Fragment Length Polymorphism , 2003, Journal of Clinical Microbiology.

[21]  E. Vinogradov,et al.  Structural analysis of Francisella tularensis lipopolysaccharide. , 2002, European journal of biochemistry.

[22]  R. Coler,et al.  Taking toll: lipid A mimetics as adjuvants and immunomodulators. , 2002, Trends in microbiology.

[23]  Samuel I. Miller,et al.  Human Toll-like receptor 4 recognizes host-specific LPS modifications , 2002, Nature Immunology.

[24]  A. Aderem,et al.  Cutting Edge: Functional Interactions Between Toll-Like Receptor (TLR) 2 and TLR1 or TLR6 in Response to Phenol-Soluble Modulin1 , 2001, The Journal of Immunology.

[25]  S. Vogel,et al.  Cutting Edge: Repurification of Lipopolysaccharide Eliminates Signaling Through Both Human and Murine Toll-Like Receptor 21 , 2000, The Journal of Immunology.

[26]  D. Schwartz,et al.  TLR4 mutations are associated with endotoxin hyporesponsiveness in humans , 2000, Nature Genetics.

[27]  K. Elkins,et al.  Purified Lipopolysaccharide from Francisella tularensis Live Vaccine Strain (LVS) Induces Protective Immunity against LVS Infection That Requires B Cells and Gamma Interferon , 2000, Infection and Immunity.

[28]  J. Baldridge,et al.  Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. , 1999, Methods.

[29]  E. Chi,et al.  Role of the type 1 TNF receptor in lung inflammation after inhalation of endotoxin or Pseudomonas aeruginosa. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[30]  Samuel I. Miller,et al.  How intracellular bacteria survive: surface modifications that promote resistance to host innate immune responses. , 1999, The Journal of infectious diseases.

[31]  Samuel I. Miller,et al.  Lipid A Acylation and Bacterial Resistance against Vertebrate Antimicrobial Peptides , 1998, Cell.

[32]  K. Watanabe,et al.  Chemical and biological properties of lipopolysaccharide from Selenomonas sputigena ATCC 33150. , 1997, Oral microbiology and immunology.

[33]  R. Darveau,et al.  A novel Escherichia coli lipid A mutant that produces an antiinflammatory lipopolysaccharide. , 1996, The Journal of clinical investigation.

[34]  R. Page,et al.  Ability of bacteria associated with chronic inflammatory disease to stimulate E-selectin expression and promote neutrophil adhesion , 1995, Infection and immunity.

[35]  D. Golenbock,et al.  Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. , 1991, The Journal of biological chemistry.

[36]  M. Caroff,et al.  Detergent-accelerated hydrolysis of bacterial endotoxins and determination of the anomeric configuration of the glycosyl phosphate present in the "isolated lipid A" fragment of the Bordetella pertussis endotoxin. , 1988, Carbohydrate research.

[37]  W. Fischer,et al.  Improved preparation of lipoteichoic acids. , 1983, European journal of biochemistry.

[38]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.

[39]  Samuel I. Miller,et al.  LPS, TLR4 and infectious disease diversity , 2005, Nature Reviews Microbiology.

[40]  C. Whitfield,et al.  Lipopolysaccharide endotoxins. , 2002, Annual review of biochemistry.

[41]  E. Rietschel,et al.  Bacterial lipopolysaccharides and innate immunity. , 2001, Journal of endotoxin research.

[42]  M. Hackett,et al.  Rapid isolation method for lipopolysaccharide and lipid A from gram-negative bacteria. , 2000, The Analyst.

[43]  J. T. Ulrich,et al.  Monophosphoryl Lipid A as an Adjuvant , 1995 .

[44]  R. Page,et al.  The ability of bacteria associated with chronic inflammatory disease to stimulate E-selectin expression and neutrophil adhesion. , 1995, Progress in clinical and biological research.

[45]  J. T. Ulrich,et al.  Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. , 1995, Pharmaceutical biotechnology.

[46]  A. Sjöstedt,et al.  Analysis of 16S ribosomal DNA sequences of Francisella strains and utilization for determination of the phylogeny of the genus and for identification of strains by PCR. , 1994, International journal of systematic bacteriology.

[47]  O. Westphal Bacterial lipopolysaccharides : extraction with phenol-water and further applications of the procedure , 1965 .